Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The action is intended to build upon the existing program for Medicare drug price negotiations, which was created by the Inflation Reduction Act that passed during the Biden administration. -
It was a chaotic week for the nation's health agencies, as layoff notices rolled in along with an order for deep cuts to contract spending. NPR's health reporters tell us what they've learned.
-
With no help from the federal government, states are trying to regulate recreational marijuana. California's Department of Cannabis Control works to keep contaminants out of joints, vapes and edibles. -
Patients who bought stockpiles of alternative GLP-1 drugs online aren't sure what to do with them after learning that the compounding pharmacy that made them didn't have the right license.
-
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare. -
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
-
The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own. -
A factory that makes IV fluids was shut down by damage from the remnants of Hurricane Helene that ripped through North Carolina. The facility could be down for months and could lead to shortages.
-
Some drugmakers are getting into the telehealth business in a move that might allow them to sell drugs directly to patients.
-
The first price negotiations between Medicare and drug companies has been underway since February. What do we know about how it's going?
